Vaginal DHEA for Women After Breast Cancer

Vaginal DHEA to Ease Vaginal Dryness in Women With a Contraindication to Estrogen Therapy

Status

Withdrawn

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01724242

Enrollment

Registered

2012-11-09

Start date

2013-02-28

Completion date

2014-12-31

Last updated

2017-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Quality of Life, Sexual Satisfaction, Urinary Incontinence, Vaginal Dryness

Keywords

Vaginal dryness, Breast Cancer, Urinary Incontinence, Quality of Life, Sexual Satisfaction

Brief summary

There does not appear to be a consensus regarding the treatment of vaginal dryness in women who have a contraindication to the use of estrogen products. DHEA, when used locally, may improve the symptoms of vaginal dryness due to its chemical properties.

Interventions

DRUGVaginal DHEA

DRUGPlacebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

FEMALE

Age

35 Years to 55 Years

Healthy volunteers

Inclusion criteria

* women post menopausal aged 35-55, suffering from vaginal dryness, secondary to chemotherapy for breast cancer, within 5 years of diagnosis. Follicle Stimulating Hormone and Estradiol levels in the post menopausal range are needed.

Exclusion criteria

* women using products to alleviate vaginal dryness. * women taking medication for urinary incontinence * women not sexually active, for other reasons.

Design outcomes

Primary

Measure	Time frame
improvement in vaginal dryness	12 weeks

Secondary

Measure	Time frame
improvement in urinary incontinence	12 weeks
improvement in sexual satisfaction	12 weeks

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026